The psychedelic sector never sits still. Here is what happened during the week of April 27 – May 3, 2026, and why each story matters for the companies and investors we track.
Helus Pharma (formerly Cybin) (HELP): Helus Pharma partners with TARA Mind to recruit veterans for HLP003 Phase 3
Helus Pharma said it is collaborating with veterans-focused organization TARA Mind to support recruitment for the PARADIGM Phase 3 program evaluating HLP003 in major depressive disorder. The partnership aims to expand mental-health awareness and trial participation within the veteran community. It signals continued execution on the company's lead depression program despite the recent CEO transition.
Source: stocktitan.net
Silo Pharma, Inc. (SILO): Silo Pharma welcomes federal psychedelic actions, touts SPC-15 PTSD candidate
Silo Pharma issued a statement welcoming a wave of coordinated U.S. federal actions accelerating psychedelic research, including ARPA-H EVIDENT awards, the FDA's issuance of three National Priority Vouchers and an IND clearance for DemeRx NB. The company highlighted its intranasal PTSD candidate SPC-15 as positioned to benefit from renewed federal focus following the April 18 executive order. Silo framed the policy shift as supportive of its preclinical-to-clinical development plans.
Source: stocktitan.net
That's the recap. Follow the Psychedelic Invest Index for how the sector is trading, and check back next week for the next edition.